# Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

> **NCT03647488** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Spartalizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03647488
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-26
- **Primary completion:** 2020-09-07
- **Final completion:** 2020-09-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647488, "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03647488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*